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G-quadruplex DNA targeted metal complexes
acting as potential anticancer drugs
Qian Cao,a Yi Li,a Eva Freisinger,b Peter Z. Qin,*c Roland K. O. Sigel*b and
Zong-Wan Mao*a
Although cisplatin and its analogues have been widely utilized as anticancer metallodrugs in clinics, their
serious side eﬀects and damage to normal tissues cannot be avoided because cisplatin kills cancer cells
by attacking genomic DNA. Thus the design of metallodrugs possessing diﬀerent actions of anti-
cancer mechanism is promising. G-quadruplex nucleic acid, which is formed by self-assembly of
guanine-rich nucleic acid sequences, has recently been considered as an attractive target for anticancer
drug design. The basic unit of a G-quadruplex is a G-quartet, a planar motif generated from four guanine
residues pairing together through Hoogsteen like hydrogen bonds. DNA G-quadruplex (G4) structures
exist in the chromosomal telomeric sequences and the promoter regions of numerous genes, including
oncogenetic promoters. Formation of G4 structures within the 3’-overhang of telomeric DNA can inhibit
the telomerase activity, which is silent in normal cells but up-regulated in most cancer cells, thus signiﬁ-
cantly shortening telomeres and preventing cancer cell proliferation and immortalization. Intramolecular
G4 structures formed within the oncogene promoter regions can eﬀectively inhibit oncogenen transcrip-
tion and expression. Thus rational design of small molecular ligands to selectively interact, stabilize or
cleave G4 structures is a promising strategy for developing potent anti-cancer drugs with selective toxicity
towards cancer cells over normal ones. This review will highlight the recent development of G4-interact-
ing metal complexes, termed G4-ligands, discussing their binding modes with G-quadruplex DNA and
their potential to serve as anticancer drugs in the medical ﬁeld.
Introduction to the international collaboration
The collaboration between Prof. Zong-Wan Mao from Sun Yat-Sen University, P. R. China and Prof. Roland K. O. Sigel from the University of Zurich,
Switzerland oﬃcially began in January, 2014. The international collaborative research project titled “Chemical Biology Research of New Metallodrugs for
Cancer Therapy” is supported by the Science and Technology Program of Guangdong Provincial Government [20130501c]. With the rapid development of
tumor molecular pharmacology, molecular targeted anti-tumor drugs have become a hot spot in the research of cancer therapy. This international collabora-
tive research project combines the computer simulation and in vitro drug screening platform to design a series of metallodrugs that are systematic and have
structural diversity, which can target specific nucleic acid structures (e.g. G-quadruplexes), key proteins (DNA topoisomerase, telomerase, CDK kinase) associ-
ated with the occurrence and development of tumor. With the advantages of both laboratories, the structural–functional relationship, interaction modes, co-
crystallization, and mechanisms of action of these newly designed metallodrugs are intensively studied, and their in vitro and in vivo anti-tumor activities are
comprehensively evaluated.
1. Introduction
In 1978 cisplatin was approved by the FDA as an anticancer
drug for clinical use. Nowadays cisplatin and its analogues are
very eﬀective chemotherapeutic agents in treating testicular
and ovarian cancers.1 However, they have several serious side
eﬀects including nephrotoxicity and ototoxicity, and their clini-
cal eﬃcacy is limited by cisplatin-resistant tumor cells. The
main reason for this is assigned to their action mechanism:
cisplatin-based drugs attack genetic DNAs, resulting in the dys-
function of transcription, translation and other processes,
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ultimately causing tumor cell death. However, such attacks do
not distinguish between tumor and normal cells, and hence
serious side eﬀects occur due to damage of normal tissues.2,3
Since then, the development of metallodrugs that possess
diﬀerent actions of mechanism has attracted great interest.2,4
One promising strategy for the design of metallodrugs is
to explore new potential biological targets rather than genomic
DNA.
G-quadruplex nucleic acids, which have structural features
very diﬀerent from the regular double helix, have recently
gained increasing interest as targets for anticancer drugs.
A G-quadruplex is formed by self-assembly of guanine-
rich nucleic acid sequences, the basic unit of which is the
G-quartet, a planar motif generated from four guanine
residues pairing together through Hoogsteen like hydrogen
bonds.5 The structures and topologies of G-quadruplex nucleic
acids have been well investigated and widely reviewed.6,7 As
shown in Fig. 1, a series of planar G-quartets stack with each
other and are connected by the intervening sequences (termed
loops), forming the G-quadruplex (G4) structure. Both
DNA and RNA G4 structures are inherently stabilized by the
presence of alkali–metal cations (most often Na+ or K+ ion)
coordinated by the guanine carbonyl oxygen atoms pointing
towards the inner channel formed at the centre of G-quartets.8
G-quadruplex structures can be formed not only intra-
molecularly within single stranded nucleic acid sequences but
also inter-molecularly from two or more individual strands.
Depending on the distinct ways the exterior loops connecting
the G-quartets and the relative orientation of the tetra-stranded
helices, G-quadruplexes display a wide range of topologies
(ca. parallel, anti-parallel, hybrid of parallel and anti-parallel,
etc.). Indeed, NMR and crystallography have been widely used
to explore the structures of G-quadruplexes, some of
which have been successfully reported either as native nucleic
acids or as complexes of G4 nucleic acids binding with small
molecules.6,7 The distinctive structures of G-quadruplexes oﬀer
a great opportunity for specific molecular recognition.
Recently, the existence of G-quadruplex DNA has been
quantitatively visualized on chromosomes in human cells,9
further motivating eﬀorts to understand the biological impli-
cations and the structural–functional relationship of G4
structures.
2. What are the biological
implications of G4 and G4-ligands?
G-quadruplex DNA predominantly exists in the chromosomal
telomeric sequences and the promoter regions of numerous
genes, such as the oncogene bcl-2, VEGF, c-myc, c-kit.10–15
Human telomeric (hTel) DNA consists of the tandem
d(TTAGGG) repeats and a single stranded 3′-overhang of
100–200 bases.16–18 In normal somatic cells human telomeric
DNA is shortened at a rate of 50–200 bp per cell division cycle,
and the accumulated telomere shortening ultimately results in
cell senescence and apoptosis. However, telomere mainten-
ance and elongation rather than telomere shortening domi-
nates in cancer cells which is the basis for cancer cell prolifer-
ation and immortalization.16 This is attributed to telomerase
activity which is silent in normal cells but up-regulated with
high activity in 85–90% of cancer cells.19 Active telomerase
hybridizes with the 3′-overhang of the telomeric DNA to
elongate the telomere thus maintaining the telomeric DNA
integrity in cancer cells. Formation of G4 structures within the
3′-overhang of telomeric DNA blocks telomerase hybridization,
resulting in the inhibition of telomerase activity thereby inter-
fering with telomere maintenance in cancer cells.20
G-quadruplex DNA formed in promoter regions also displays
significant biological roles especially in modulating gene
transcription.10–14 Prior to transcription the duplex DNA tran-
siently unwinds to release the G-rich single strand from the
complementary C-rich strand. Once the single-stranded G-rich
sequence folds into a stable G-quadruplex, its access to the
promoter will be blocked thereby down-regulating transcrip-
tion. Thus rational design of small molecule ligands to selec-
tively interact and stabilize either or both hTel G4 and promo-
ter G4 of oncogenes has been identified as a promising
strategy for the development of anti-cancer drugs with selective
toxicity towards cancer cells over normal ones.21
Although much research has focused on G4 DNA,
G-quadruplex RNA exists within the non-coding telomeric
r(UUAGGG) repeats (TERRA) and untranslated regions
(5′-UTRs) of mammalian mRNA sequences.22–25 G-quadruplex
formation within the nascent RNA blocks the progress of the
ribosome complex formation thereby down-regulating trans-
lation.24 Compared to equivalent G4 DNA sequences, G4 RNA
is much more stable, invariably folding into parallel topology,
and widely distributed in the entire cell including cytoplasm
which makes it easier to access than DNA. Thus G-quadruplex
RNA is also considered a potential target for anticancer drugs,
and lately considerable research eﬀort has focused on
RNA-directed drug design that can selectively target
G-quadruplex RNA.26,27
Indeed, the development of small molecules that can recog-
nize and bind to the G-quadruplex with high aﬃnity and
Fig. 1 (A) Schematic representation of a G-quartet and its stacking to
form an intramolecular G-quadruplex structure. (B) Diﬀerent topologies
of G-quadruplex arranged intermolecularly and intramolecularly.
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specificity over duplex nucleic acids, termed G4-ligands, has
become a progressively large field of research with rapidly
increasing numbers of reported molecules as well as excellent
reviews.28,29 The representative member is a first-in-class
in vivo G4-ligand, named as CX3543 (also known as
Quarfloxin), which has reached phase II clinical trials for treat-
ing neuroendocrine tumors and carcinoid tumors.30 Besides
purely organic G4-ligands, metal complexes acting as small
molecule G4-ligands have recently attracted a lot of interest, as
they interact strongly and selectively with quadruplex nucleic
acids.28,31 Compared with organic molecules, metal complexes
possess characteristic structural features, various charges, and
additional electromagnetic properties providing advantages
for the construction of G4-ligands. For example, the synthesis
is very regular and much easier; the geometry is variable and
controllable (e.g. planar, octahedral, tetragonal pyramidal, etc.)
which is predominately determined by the coordination geo-
metry surrounding the metal centre. Such a variety of geome-
tries provides a greater number of action modes: planar mole-
cules favour p-stacking with G-quartets, including end-stacking
and intercalation, but also alternative modes such as groove/
loop binding, electrostatic interactions, and direct coordi-
nation to bases or the phosphate backbone are possible. In
addition, the central metal ions and suitable substituted
ligands oﬀer cationic properties to the entire molecule which
is preferable for stronger electrostatic interactions with electro-
negative nucleic acids and easier cell permeability. Certain
metal complexes possess interesting optical, magnetic, or cata-
lytic properties and thus show additional functions and anti-
cancer properties. For example, optical properties including
large stokes shifts, high quantum yields, long-lived lumine-
scence, and good photostability allow one to trace the behav-
iour of these metal complexes in real-time in living cells,
thereby at the same time acting as theranostic agents and
G-quadruplex probes. These unique properties of metal
complexes make them ideal candidates for constructing novel
G4-ligands.
This review highlights the recent developments of G4-tar-
geting metal complexes, termed G4-ligands, discussing their
binding modes with the G-quadruplex, their inhibition eﬀect
on telomerase activity, their interference with gene transcrip-
tional and translational regulation, and their potential to act
as anticancer drugs in the clinics. Although G4 RNA also pos-
sesses significant biological roles in cancer biology, to the best
of our knowledge the only report of metal complexes acting as
RNA G4-ligands is a bimetallic platinum(II)-modified perylene
derivative reported by Bierbach et al.32 Thus this review will
only cover the reported metal complexes acting as DNA G4-
ligands. Generally speaking, these compounds achieve their
anticancer potential by inducing or stabilizing G-quadruplex
formation through various binding modes, thus aﬀecting
gene transcription and expression (promoter G4) or inhibiting
telomerase activity (telomere G4). In a few cases, metal-
containing G4-ligands can even induce cross-linking or
cleavage of G-quadruplex DNA, ultimately achieving anticancer
properties.
3. Methods for studying ligand/
G-quadruplex interactions
A wide variety of biophysical and biochemical techniques have
been employed to investigate the interactions of G4-ligands
and their eﬀect on telomerase activity and gene expression
regulation.33 Usually the combination of more than one tech-
nique is required for a detailed understanding of G4-ligand
interactions. Optical spectroscopy, including UV-visible
(UV-Vis), fluorescence resonance energy transfer (FRET), and
circular dichroism (CD), is one of the routinely used tech-
niques capable of determining, e.g., the melting temperature
of the G-quadruplex in the presence of G4-ligands via the spec-
tral changes, thus providing crucial information about G4-
ligand interactions, such as stoichiometry, stabilization
potency and especially the selectivity for quadruplex in com-
parison to duplex DNA. These optical methods are rapid, non-
destructive and only require small amounts of material.
Moreover, the G-quadruplex has various topologies and CD
spectroscopy can monitor conformational transitions. For
example, the characteristic spectrum of an antiparallel G4
structure shows a positive band at 295 nm and a negative band
at 265 nm, while both a negative band at 240 nm and a posi-
tive band at 275 nm are signatures of a parallel G4 structure.
Taking a propeller-shaped trinuclear Pt(II) complex {[Pt
(dien)]3(ptp)}(NO3)6,
34 which has recently been reported by our
group as an example (complex 165 in Fig. 15), FRET melting
curves and stabilization temperature (ΔTm) values obtained in
the presence of 0.5 μM Pt(II) complex showed that this complex
has little eﬀect on the duplex DNA (ΔTm = 0.4 °C), but induces
an appreciable increase in thermal stability (ΔTm = 30.2 °C) in
hTel G4 sequences, indicating excellent selectivity towards the
G-quadruplex. Titration of this complex to the hTel d
[AG3(T2AG3)3] sequence, in the presence of either K
+ or Na+,
induces characteristic CD signatures of an antiparallel G4
structure even at a low complex/DNA ratio (r = 0.2–1.5), indicat-
ing that this complex likely induces and stabilizes the anti-
parallel G4 topology.
To quantitatively analyse G4-ligand interactions, two comp-
lementary methods, isothermal titration calorimetry (ITC) and
surface plasmon resonance (SPR), have been extensively used
to determine the kinetic and thermodynamic parameters of
the binding events, including binding aﬃnity, dissociation
constant, enthalpic and entropic contributions of the binding
process, etc.33 These parameters provide crucial information
for understanding the driving force for ligand/quadruplex
complex formation, evaluating the selectivity of the G4-
ligands, and to some degree revealing the binding modes.
However, all the biophysical techniques mentioned above
cannot provide precise structural information. For the develop-
ment of excellent G4-ligands with high aﬃnity and specificity,
it is important to determine the structural parameters of
ligand/quadruplex interactions including precise binding sites
and binding modes at the molecular level. Such structural
information can be obtained by X-ray diﬀraction and NMR
Review Inorganic Chemistry Frontiers
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spectroscopy, and until now a variety of resolved structures of
ligand/G-quadruplex complexes have been reported and
reviewed.8,29,35–37 Among them, the first crystal structure of a
hTel G4 DNA bound to a metal–salphen complex (copper or
nickel) was reported by Campbell et al. in 2012.38
Besides the described biophysical methods, several in vitro
biochemical methods have also been developed to assess the
capability of G4-ligands to induce and stabilize the
G-quadruplex, to inhibit telomerase activity, to accelerate telo-
meric shortening, and to inhibit oncogene expression. Here we
focus on two usually employed PCR-based methods, the PCR-
stop assay and in vitro TRAP (Telomere Repeat Amplification
Protocol) assay.33 In a PCR-stop assay the G4-ligand induced
formation and stabilization of a G-quadruplex structure within
the DNA sequence will reduce or even inhibit DNA synthesis,
resulting in decreased formation or complete absence of the
PCR product. The IC50 value obtained in a PCR-stop assay indi-
cates the concentration of G4-ligands required to achieve 50%
inhibition of the amplification reaction. Telomerase activity
can be evaluated by the in vitro TRAP assay, which involves
three steps: initial primer elongation by telomerase in the
absence or presence of G4-ligands, removal of the G4-ligands
and then PCR amplification of the telomerase elongation pro-
ducts. The obtained IC50-TRAP value is defined as the concen-
tration of G4-ligands required for inhibiting telomerase activity
by 50%. Taking again the propeller-shaped {[Pt(dien)]3(ptp)}
(NO3)6 complex as an example (vide infra, complex 165 in
Fig. 15),34 increasing concentrations of the Pt(II) complex
indeed decrease the amount of PCR products (dsDNA) with a
complete PCR stop observed in the presence of 3.0 µM of Pt(II)
complex, confirming that this complex can induce and stabil-
ize hTel G4 structure. Simultaneously this complex exhibits
eﬀective inhibition towards telomerase activity in a concen-
tration-dependent manner with an IC50-TRAP value of 16.0 ±
0.40 µM.
In addition to the techniques described above for investi-
gating metal complex/G-quadruplex interactions and the anti-
cancer properties of G4-targeted metal complexes, other
eﬃcient and robust biophysical techniques and in vitro assays
are also available to monitor the ligands/G-quadruplex inter-
actions, such as mass spectrometry, surface-enhanced Raman
spectroscopy, single-molecule fluorescence imaging, equili-
brium dialysis, gel electrophoresis, translational assay as well
as molecular modelling. These are not described in detail here
as their applications to metal complexes have been limited.
4. G-quadruplex targeting metal
complexes
4.1. Cisplatin derivatives – platination of G-quadruplex
In spite of the disadvantages of its unselective binding to
genetic DNA, cisplatin is still the most successful anticancer
drug in clinical use. Thus the development of rationally
designed cisplatin derivatives acting as specific DNA G4-
ligands also attracts a lot of attention. Similar to cisplatin,
these derivatives also contain labile groups (Cl, H2O, etc.)
making direct coordination of the platinum centre to G4 DNA
nucleobases highly probable. This type of coordination is tra-
ditionally denoted as platination and can occur either at a
single-site or lead to cross-linking of two nucleobases, in most
cases, guanines. For example, cross-linking of two guanine
bases or of an adenine-and a guanine base was observed after
platination of a preorganized G-quadruplex with [Pt
(NH3)2(H2O)2](NO3)2 (cis or trans), the action pattern of which
is similar to cisplatin.39 A dimetallic cisplatin derivative (1 in
Fig. 2) can also cross-link two guanine bases and the cross-
linking position was located at the terminal G-quartets.40 In
addition, an interesting Pt–ACRAMTU complex 2 (Fig. 2)
showed an abnormal kinetic preference for platination at
adenine (N7 site) over guanine, and more interestingly, HPLC
analysis of the reaction between DNA and Pt–ACRAMTU
showed that the amount of the Pt–G4 adducts exceeds the
corresponding Pt–duplex DNA adducts, indicating some
binding selectivity of this complex towards G4 DNA.41
Cisplatin derivatives containing a planar aromatic ligand
suitable for π-stacking with the G-quartets allows interactions
with the G-quadruplex through a double noncovalent/covalent
binding mode. For example, a Pt(II)–MPQ complex 3 (Fig. 2)
was constructed by linking cisplatin with a planar quinacri-
dine aromatic moiety through a long hydrophilic linker, the
length of which was suitable for spanning the length of the
G-quartet stacks.1,42 Such structural features allow the quina-
cridine plane to end-stack on one face of the G-quartets and
the Pt(II) metal centre to platinate a tetrad guanine base on the
opposite face, ultimately stabilizing the antiparallel topology
of a 22-mer G4 DNA. Very recently, two organoplatinum com-
plexes 4–5 (Fig. 2) have also been reported containing both the
labile chloride atom and a π-conjugated planar aromatic
ligand (1-azabenzanthrone or 6-hydroxyloxoisoaporphine alka-
loid), which allowed platination at guanine nucleobases of the
G-quadruplex as well as the non-covalent π-stacking with
Fig. 2 Cisplatin derivatives reported as G4-ligands, the binding mode
of which is mainly direct platination (single-site coordination or cross-
linking of two nucleobases).40–43 Complex 3 utilized a double noncova-
lent/covalent binding mode.42
Inorganic Chemistry Frontiers Review
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G-quartets.43 The in vitro and in vivo anticancer eﬃcacies of
these two Pt(II) complexes were also investigated in cisplatin-
resistant tumor cells and xenograft models, respectively.
4.2. Metalloporphyrins and derivatives
In the examples presented above, the Pt(II) metal centre coordi-
nates directly to G4 DNA bases. However, most of the reported
metal-containing G4-ligands interact with G4 DNA through
non-covalent binding. The earliest reported metal complexes
acting as G4-ligands are metalloporphyrins, the binding mode
of which was proposed to be π-stacking on top of the terminal
G-quartets (termed end-stacking), similar to the free
porphyrins.44–46 TMPyP4, a cationic meso-methylpyridinium-
substituted porphyrin, was reported in 1998 to be capable of
stabilizing the human telomeric G4 DNA by end-stacking on
the terminal G-quartets and inhibiting telomerase activity
(IC50-TRAP = 6.5 ± 1.4 μM).47 The cationic properties of
TMPyP4 enable electrostatic interactions with the negative
backbone of G4 DNA, and hence a higher binding aﬃnity is
observed compared to porphyrin. Subsequently, a series of
TMPyP4 complexes with various metal centres, including
main-group metals and transition metals (Ni(II), Mn(III),
Mn(V)vO, Mg(II), Cu(II), Zn(II), Pd(II), Pt(II), Fe(III), Co(II), In(III),
etc.) have been synthesized and investigated. All these metal–
TMPyP4 complexes (6–16 in Fig. 3) eﬃciently stabilize the hTel
quadruplex and inhibit telomerase activity in vitro, due to the
cationic charge and the π-stacking abilities (either end-stack-
ing or intercalation) of the complexes described above. The
stoichiometric ratio of ligand/G-quadruplex was found to be
2 : 1 in most cases.45,46
The metal centre plays a critical role in the ligand/
G-quadruplex interactions including binding aﬃnity, specificity,
as well as telomerase inhibiting activity. For example, although
the nickel(II)–TMPyP4 complex 6 was reported as a potent
inhibitor of telomerase with an IC50-TRAP value of 5 μM, its
binding aﬃnity for G4 DNA is unfortunately one order of
magnitude lower than that for duplex DNAs (106 M−1 vs. 107
M−1) in a SPR assay.48,49 In comparison, the manganese(III)–
TMPyP4 complex 7 displays similar telomerase inhibition
potency to the free TMPyP4 ligand itself, but shows at least
10-fold better selectivity for the quadruplex over duplex
DNA.48,49 Changing the metal centre from Mn(III) to Zn(II) main-
tains the selectivity for quadruplex as well as the telomerase
inhibition potency.50 Interestingly, the Zn–TMPyP4 complex 11
was found to be capable of inducing the formation of
parallel G4 topology for some specific sections of single-
stranded DNA.50 Cu(II)–TMpyP4 complex 10 and its analogue 17
(Fig. 3) also attracted attention because copper is an
essential element for human living.51,52 10 and 17 both stabilize
the hTel quadruplex and inhibit telomerase activity in vitro.
Upon titration of the parallel G-quadruplex, a large hypochro-
mic eﬀect in the UV-Vis spectra accompanied by an induced
negative band at 240 nm in the CD spectra was observed,
indicating a binding mode via the intercalation of the square-
pyramidal geometry between the G-quartets of the
G-quadruplex. Gold(III)–TMPyP4 complex 19 was also reported
as an hTel G4 stabilizer and a potent telomerase inhibitor,
which was proven by the eﬀective inhibition of the PCR amplifi-
cation of a G4 sequence in the PCR-stop assay and the observed
57% inhibition rate of telomerase, Moreover, this Au(III)
complex showed low cytotoxicity (IC50 > 50 μM) against normal
nasopharyngeal cells.
Besides the metal centre, the choice of the meso substitu-
ents on the porphyrin is another critical parameter influencing
the interaction with G4. For example, when one or two meso-
methylpyridinium groups of the TMPyP4 are replaced by one
or two long 4-aminoquinoline moieties, new metallopor-
phyrins were constructed, probably enhancing the G4 aﬃnity
and cell wall penetration (Fig. 4). Such modified manganese(III)
complexes 22 and 28 show greater telomerase inhibition
than the unmodified Mn(III)–TMPyP4 complex 7, with lower
IC50-TRAP values of 11.5 and 8.6 μM, respectively.49 The
binding rate was found to be fast in kinetic experiments
suggesting the stacking of the quinoline substituents with a
G-quartet. When one meso-methylpyridinium group of the
TMPyP4 is replaced by a simple polyamine side chain, the
Mn(II) complexes 24 show a relatively high aﬃnity (nearly 108
M−1) for quadruplex DNA, although this was not accompanied
by improved selectivity.48 Upon replacement of all four meso-
methylpyridinium groups of the TMPyP4 ligand by four flex-
ible bulky cationic moieties, the most impressive pentacationic
manganese(III)–porphyrin complex 20 was constructed, which
has a high aﬃnity (nearly 108 M−1) for quadruplex DNA as well
as 10 000-fold selectivity towards G4 over duplex DNA.54 Such a
Fig. 3 Metal–TMPyP4 complexes and derivatives reported as G4-
ligands. The metal centres in complexes 6–16 are Ni(II), Mn(III), Mn(V)vO,
Mg(II), Cu(II), Zn(II), Pd(II), Pt(II), Fe(III), Co(II), In(III), in 17–18 Cu(II) and Zn(II),
and in 20–21 Mn(III) and Ni(II), respectively.44–54
Review Inorganic Chemistry Frontiers
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high selectivity can also be explained by the steric eﬀect of the
bulky side arms preventing the intercalation of the complex
into the duplex DNA as similarly described for porphyrin-
bridged tetranuclear platinum complexes. In contrast, apply-
ing the same modifications mentioned above to the Ni–
TMPyP4 analogues 21, 23, 25 does not increase the G4 aﬃnity,
the selectivity or the telomerase inhibition activity. These
modified Ni–TMPyP4 analogues cause inhibition of telomer-
ase-mediated elongation of the telomere primer at 7–39 μM in
the TRAP assay, and hence the inhibition eﬀect is even lower
than that of the unmodified Ni–TMPyP4 complex 6.49
In addition, binuclear manganese/nickel–porphyrin deriva-
tives 26–27 were synthesized with a linker of appropriate length
linking the symmetric porphyrinic dimer. This design proposes
a sandwich-type binding mode with the quadruplex DNA struc-
ture in theory, but these complexes were shown to be ineﬃcient
for stabilizing or discriminating G4 over the duplex.48
Our group also reported two clover-like shaped, porphyrin-
bridged tetranuclear platinum complexes 29–30 (Fig. 5).55
Diﬀerent from the complexes mentioned above, the Pt(II) ions
are coordinated at the side arms providing high positive
charges in the compounds and probably increasing the overall
steric hindrance, which helps end-on stacking and prevents
intercalation into duplex DNA. Indeed, both of them were
found to eﬀectively stabilize various kinds of G-quadruplexes
(hTel, c-myc, c-kit and bcl2) in the parallel topology with high
aﬃnity but displayed negligible eﬀects on the duplex. The π–π
end-stacking binding mode was proven by the hypochromic
eﬀect in UV/Vis spectra and unquenched fluorescence upon
titration of the G4 sequence. Furthermore, the maximum
binding ratio of 4 : 1 ([complex]:[G4]) indicates the presence of
other binding modes such as groove interactions. The clover-
like shaped platinum complexes showed excellent anticancer
activity that was attributed to a dual eﬀect, the inhibition of
telomerase activity (IC50-TRAP = 1.46 μM and 0.25 μM) and the
repression of oncogene expression, ultimately inducing apop-
tosis and G2/M phase arrest in HeLa cells. Another special
case is the ruthenium(II) polypyridyl complex 31 having a pyri-
dine ligand attached to a porphyrin.56 Although the Ru(II)
metal core determines the octahedral geometry of this com-
pound, the planar porphyrin ligand results in a high aﬃnity to
the hTel G4 accompanied by hypochromism eﬀects in UV/Vis
spectra.
These investigations indicate that the central aromatic core
(TMPyP4 moiety) might be predominantly responsible for the
interactions between metalloporphyrines and G4. The side
arms also play significant roles, helping to improve the
binding aﬃnity and selectivity over the duplex depending on
the rational design.
4.3. Metallophthalocyanines and derivatives
Phthalocyanine, a porphyrin derivative featuring aromatic
rings fused to each pyrrole moiety of the basic porphyrin
Fig. 4 Metalloporphyrins with various meso-substituents reported as G4-ligands.48,49
Fig. 5 Porphyrin-bridged tetranuclear Pt(II) complexes and a mono-
nuclear Ru(II) complex containing a porphyrine-like ligand.55,56
Inorganic Chemistry Frontiers Review
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skeleton with nitrogen atoms in the meso-positions, provides a
more extended aromatic surface preferred for end-stacking on
a terminal G-quartet. A series of metallophthalocyanines,
especially with zinc(II) and nickel(II) as metal centres, have
been reported as novel and potent telomerase inhibitors
(Fig. 6).57–61 The phthalocyanine skeleton of these complexes
was modified by introducing four or eight cationic oxygen/
sulfur armed quaternary ammonium on the fused aromatic
rings (complex 32–39), increasing the number of cationic
charges and enhancing the steric hindrance, both of which
made the complexes more favourable G4 binders. Compared
to the corresponding metalloporphyrins, these
metallophthalocyanines display enhanced binding aﬃnities
and selectivity for the G-quadruplex over duplex DNA. For
example, the Zn(II) complex 38 with eight cationic quaternary
ammonium exhibits strong electrostatic interactions with
grooves or loops, contributing to the approximately 6-fold
G-quadruplex selectivity over duplex DNA and very eﬀective tel-
omerase inhibition (IC50-TRAP = 0.23 μM). Moreover, this
complex prefers to induce conformational transitions from
antiparallel to parallel G-quadruplex even in alkali–metal
deficient buﬀer.60 By comparison, the Zn(II) analogue 47 with
fewer positive charges (4+) and less steric hindrance prefers an
antiparallel G4 topology in alkali–metal deficient buﬀer.61 A
series of Zn(II) complexes with amido-armed phthalocyanines
(41–46) were also reported with excellent aﬃnities for hTel G4
as well as a metallophthalocyanine was reported in 2009: the
guanidinium–parallel G4 with high aﬃnity. When interacting
with c-myc G-quadruplex DNA the dissociation constant is
only 2 nM, which is the strongest binding interaction among
all reported small molecule-based G4-ligands.57,58 These
investigations indicate that both the planar phthalocyanine
moiety and the highly positively charged side arms contribute
to the favourable binding to G-quadruplex as well as the telo-
merase inhibition potential.57,58
4.4. Metallocorroles and derivatives
Another porphyrin derivative is the corrole ligand, which pro-
vides additional geometries and electronic properties for the
eﬀective stabilization of transition metal ions in high oxi-
dation states. A series of metallocorroles, mainly with Cu(II) or
Mn(III) as metal centres (Fig. 7), were reported as eﬀective G4-
ligands and potent telomerase inhibitors.62–64 Interestingly,
Fig. 6 Metallophthalocyanines and derivatives with four or eight cationic side arms reported as G4-ligands.57–61
Fig. 7 Metallocorroles with cationic side arms reported as G4-
ligands.62–65
Review Inorganic Chemistry Frontiers
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these complexes have typically a saddle-type geometry opposed
to the planar metalloporphyrins. One example is the water-
soluble, saddle-shaped, meso-methylpyridinium-substituted
Mn(III)–corrole complex 48.62,63,65 Due to the favourable shape
and high electron deficiency, this Mn(III)–corrole complex exhi-
bits 64-fold selectivity towards G4 over duplex DNA according
to the binding constant values and prefers to induce hybrid G4
topology according to the CD characteristic signatures. In a
PCR-stop assay, this complex eﬀectively induces and stabilizes
hTel and c-myc G-quadruplex DNA with the IC50 values of 2.37
and 1.52 μM, respectively. The Cu(II)–corrole complex with the
same meso-methylpyridinium substitution as the Mn(III)–
corrole complex 48 was reported to be as eﬀective and selective
in G4 stabilization, the activity of which was slightly lower
than that of the corresponding Mn(III)–corrole complex.62 Its
binding constant to G-quadruplex DNA was found to be
50-fold greater than that to duplex DNA, and the IC50 values
obtained in the PCR stop assay are 3.51 and 2.74 μM, respect-
ively, for hTel and c-myc. CD spectra showed that this complex
also prefers to induce the parallel-to-hybrid conformational
transitions of the hTel G4 sequence. Further Cu(II)–corrole
complexes (49–54), modified by introducing three meso-substi-
tuted benzene ring-armed pyridinium or quaternary
ammonium moieties through diﬀerent linkers into the corrole
skeleton, were also investigated as G4-ligands.62 Such modifi-
cations increase the number of cationic charges which
promotes electrostatic interactions with the negatively charged
DNA backbone as mentioned above. Both CD spectra and
PCR-stop assay indicated that these complexes are good at
stabilizing G4 in the presence of micromolar Na+ concen-
tration, and that some of them induce antiparallel G4
topology.
4.5. Metal–salphen and metal–salen complexes
Besides macrocyclic metal complexes, planar metal complexes
with nonmacrocyclic polydentate ligands acting as eﬀective
G4-ligands have also attracted ample attention. A representa-
tive group of these complexes are metal–salen and metal–
salphen complexes, which have previously been proven to be
capable of intercalating into duplex DNA through π–π stack-
ing.66,67 A series of comparative metal–salphen complexes with
similar polydentate ligands but diﬀerent metal ion centres
were constructed (Fig. 8). Crystal structures revealed that Ni(II)
complexes 55–64 and 73–82, Cu(II) complex 65 and Pt(II) com-
plexes 68–72 have a planar geometry,68–71 whereas the penta-
coordinated V(IV)vO complex 67 has a quasi-planar geome-
try69,72 and the Zn(II)(H2O) complex 66 is non-planar.
69
According to FRET, FID and SPR assays, all these planar
metal–salphen complexes are eﬀective G4 stabilizers whereas
non-planar metal–salphen complexes only show low G4
aﬃnity or specificity. For example, the melting temperature of
telomeric G4 was increased by 33, 21.5 and 10.5 °C in the
presence of the planar Ni complex 55, the Cu complex 65 and
the quasi-planar VvO complex 67, respectively, whereas non-
planar Zn(II)(H2O) complex 66 only increased the melting
temperature of G4 by 1.4 °C. These planar compounds were
Fig. 8 Metallosalphens with various side arms reported as G4-ligands.66–73
Inorganic Chemistry Frontiers Review
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found to be highly selective for the G-quadruplex over duplex
DNA, e.g. 50-fold selectivity of Ni–salphen complexes as
reflected by the equilibrium dissociation constants of:
0.1–1.0 μM for the G-quadruplex vs. 2.0 μM for duplex DNA.
The interaction mode of the planar metal–salphen complexes
with the G-quadruplex was proposed based on molecular mod-
elling: the planar aromatic surface of the complex stacks on
the terminal G-quartet with the exterior cationic side chains
inserted into the opposite grooves. It is worth mentioning that
a co-crystallization of a typical square-planar Ni–salphen com-
pound 57 complexed with the telomeric G4 DNA in parallel
topology was successfully obtained.68 The TRAP assay also
proved the potent telomerase inhibition activity of these
metal–salphen complexes resulting in IC50 values in the low
micromolar or even nanomolar range.
Despite the inability of the salphen ligand itself to π-stack
with and stabilize G-quartets due to its flexible geometry, the
coordination with suitable metal ions often induces a planar
geometry and arranges the aromatic rings around the central
metal ion in an optimal structure to enhance π–π stacking
between the metal–salphen complexes and G4 structures.
Moreover, the modification of the salphen ligand in metal
complexes by, for example positively charged quaternary
ammoniums, alkyl–imidazolium side chains, or cyclic amine-
based side chains which can be protonated under physiologi-
cal conditions, enhances the binding aﬃnity with G4 by
electrostatic interactions of the protonated side arms with the
loops and grooves of the DNA backbones. All these factors
(overall geometry, charge, modification on the salphen ligand)
also dictate the selectivity of the metal–salphen complexes
towards G-quadruplexes. For example, the Pt(II)–salphen
complex 72 with cyclic amine-based side chains was reported
to eﬀectively stabilize the c-myc promoter G4 structure by end-
stacking with the terminal G-quartets, resulting in the inhi-
bition of oncogene expression both in a cell-free system and in
cultured cells.73 It is worth mentioning that this complex
modified with cyclic amine-based side arms exhibited a
10-fold higher inhibition activity than the non-modified
complex. Moreover, several Pt(II)–salphen complexes such as
72 possess additional fluorescence emissive properties capable
of showing their cellular uptake and localization in living cells
by using confocal microscopy.71
A series of Ni(II), Cu(II) and Pt(II) based metal–salen com-
plexes 83–91 with suitably modified salen ligands were also
reported to act as eﬃcient G4-ligands, illustrating again the
significance of the planar geometry and modifications on the
side arms for improving G4 binding (Fig. 9).73–75 For example,
a planar Ni(II)–salen complex 87 with quaternary ammonium
side chains is capable of selectively stabilizing an oncogene
promoter G4 over duplex DNA, as shown by UV/Vis, CD and
FRET assays.74 Another two interesting Ni(II)–salen complexes
90–91 with cyclic amine-based side chains were also investi-
gated, the salen ligand of which contained the meso-1,2-
diphenylethylenediamine moiety.75 Compared with the corres-
ponding Ni(II)–salphen complex 63–64, the presence of the
meso-1,2-diphenylethylenediamine moiety provides steric
hindrance eliminating the possibility of intercalation with
duplex DNA, thus oﬀering a slightly better selectivity for either
a unimolecular or intermolecular G-quadruplex over duplex
DNA.
4.6. Metal–phenanthroline complexes and derivatives
Another representative group of planar non-macrocyclic poly-
dentate metal complexes are square-planar Pt(II)–phenanthro-
line complexes, in which the phenanthroline moiety is
replaced by analogues such as bipyridine, phenylpyridine,
dipyridophenazine, or phenanthroimidazole (Fig. 10). The
Pt(II) centre with its positive charges is essential for DNA
binding, the square-planar geometry of these complexes again
promote π–π stacking with G-quartets. Comparative studies
illustrated that ligands possessing an extended π surface
favour G4 interactions. For example, both Pt(II) complexes 94
with bis-phenathroline76 or phenanthroline–ethylenedi-
amine77,78 stabilize G-quadruplex structures, the interaction
being stronger than with the bis-bipyridine and bipyridine–
ethylenediamine analogues 92–93.76–78 Upon replacement of
the phenanthroline by a phenanthroimidazole moiety, the
latter possessing an extended π-delocalized surface and an aro-
matic pendant, the selectivity of the platinum complexes
102–103 towards G4 improved and the aﬃnity constants for G4
binding were two orders of magnitude larger than binding to
duplex DNA.77,79,80 Organoplatinum complexes usually exhibit
excellent photophysical properties, e.g. organoplatinum(II)–
dipyridophenazine complexes 96–99 with C-deprotonated
2-phenylpyridine ligands. Upon interaction with G4 DNA, the
emission intensity of the complexes is greatly enhanced.81
Fig. 9 Metallosalens with various side arms reported as G4-
ligands.73–75
Review Inorganic Chemistry Frontiers
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These photophysical experiments also provide additional evi-
dence supporting the end-stacking binding mode for G4 DNA.
The binding aﬃnity in the order of 106–107 M−1 for G4 DNA is
stronger than for the phenanthroline complexes and at the
same time potent inhibition of telomerase activity in in vitro
TRAP assays is observed.81
Similar phenanthroline complexes with other metal centres
106–109 are also eﬀective G4 DNA binders capable of dis-
tinguishing G4 and duplex DNA (Fig. 10).82,83 For example, the
Mg(II) complex with bis-phenathroline selectively increases the
melting temperature of G4 DNA but displays only a negligible
eﬀect on the melting temperature of duplex DNA, illustrating
selective G4 stabilization.82 In the case of the Ni(II) complex
with the phenanthroline–ethylenediamine ligand, the in situ
formation of the complex/hTel G4 DNA adduct was directly
observed by electrospray ionization mass spectrometry
(ESI-MS).83 A penta-coordinated Au(III) pyrazolylpyridine
complex 106 interacts strongly and selectively with quadruplex
DNA, in particular with c-myc, through π–π stacking. This is
the first example of an Au(III) complex based G4-ligand.84
4.7. Metal–terpyridine complexes and derivatives
Metal–terpyridine complexes with Cu(II), Zn(II), Pt(II) and Pd(II)
ion centres can act as eﬀective G4-ligands (Fig. 11 and 12).85–88
The central metal ion, the number of aromatic rings, as well as
the number and position of the substituents on the terpyridine
scaﬀold play critical roles for G4 recognition and stabilization.
A series of comparative studies of metal–terpyridine complexes
demonstrated that the binding aﬃnity and selectivity for G4
DNA depend mainly dependent on the geometry of the
complex. Here the eﬀective G4 stabilizers must exhibit at least
one planar aromatic surface accessible for π–π stacking inter-
actions with G-quartets. Thus the capability of the zinc(II) ter-
pyridine complexes 110–111 for G4 binding was poor due to
their nonplanarity as reported by Teulade-Fichou et al.85
whereas similar Cu(II) 113–114 and Pt(II) complexes 131–132 as
reported by Bertrand et al.85 and Wang et al.86, respectively, are
good G4 stabilizers due to their planar geometry.
The modification of terpyridine by attaching additional aro-
matic rings, charged peralkylated ammonium, cyclic amine-
Fig. 10 Metal–phenanthroline complexes and derivatives reported as G4-ligands. The bidentate ligands are, e.g. ethylenediamine (dien), bipyridine
(bpy), phenanthroline (phen), dipyridophenazine (dppz), phenanthroimidazol, phenylpyridine (ppy). Several Pt(II) complexes are also luminescent
G4-ligands.76–84
Inorganic Chemistry Frontiers Review
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based side chains, or another suitable pendant improves the
binding aﬃnity and selectivity of the metal–terpyridine com-
plexes for G4-quadruplex.46–88 For example, Bertrand et al.
designed a range of copper–terpyridine complexes, among
them complexes with ttpy 113 and ctpy 114, that display a
better aﬃnity and selectivity for G4 DNA (ΔTm = 15.3 and
10.0 °C, respectively) than complex 112 which carries a simple
tpy ligand (ΔTm = 1.0 °C).85 Another example is a group of
Cu(II)– and Pt(II)–terpyridines 118–121 constructed by Gama
et al., in which the terpyridine is tethered with a planar anthra-
cene moiety via diﬀerent linkers.87 All these complexes are
potent G4 stabilizers and telomerase inhibitors, exhibiting
good aﬃnity and selectivity for the G-quadruplex over duplex
DNA. It is interesting to note that the strength of the ligand/G4
interactions increases with the linker size between the anthra-
cenyl moiety and the terpyridine chelating unit.
The extension of the planar aromatic surface of the terpyri-
dine scaﬀolds also enhances the binding aﬃnity and specificity
of metal complexes for G4 DNA. Several N-donor tridentate (ter-
pyridine-like) ligands with a more extended planar aromatic
surface than the simple terpyridines were designed. The corres-
ponding Pd(II), Cu(II) and Pt(II) complexes 125–129 exhibit an
enhanced binding aﬃnity and specificity for G4 DNA (Fig. 11).89
It is interesting to note that the Pd(II) complex 129 exhibits a
better stabilization eﬀect on G4 DNA than the corresponding
Pt(II) and Cu(II) complexes 128 and 130 according to the FRET
assay. The ESI-MS and UV/Vis measurements suggest that the
Pd(II) complex possesses the greater ability to eﬀectively coordi-
nate DNA bases at room temperature whereas the Pt(II) complex
predominately binds non-covalently to G4 DNA.
Here we concentrate on platinum(II)–terpyridine complexes
as these are most widely studied (131–146 in Fig. 12).85,88,90,91
Besides very few examples with a sulfur atom-armed cyclic
amine as the monodentate ligand, most reported platinum(II)–
terpyridine complexes can be divided into two main groups:
the monodentate ligand is either a labile chloride or an
alkynyl moiety, both ensuring a planar geometry of the
complex optimal for G4 interactions through π stacking. The
presence of the labile chloride allows the possibility of direct
coordination of the platinum(II)–terpyridine complex to G4
DNA.85,88,90,91 For example, the complexes 131–132 can inter-
act with a telomeric G4 sequence with good aﬃnity–selectivity
via platination of the adenine residues in the loops.42
However, a labile chloride does not ensure platination of G4,
for e.g. the complex 146,89 carrying a bis-quinolino modifi-
cation on the terpyridine, not only exhibits a larger
π-delocalized surface but also extensive steric hindrance,
resulting in no platination of G4 DNA.
Fig. 11 Metal–terpyridine complexes and derivatives reported as G4-ligands.85–89
Review Inorganic Chemistry Frontiers
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Members of the second group 142–145 with an alkynyl
moiety as the monodentate ligand, not only act as good G4
stabilizers with high aﬃnity and selectivity but also exhibit
excellent optical properties. Hence the Pt(II) terpyridyl alkynyl
complexes can be additionally used to monitor the
G-quadruplex.86,92 Furthermore, the terpyridine ligands of all
these Pt(II) complexes were modified with additional aromatic
rings, or cyclic amine- or peralkylated ammonium-based side
chains, resulting in an enhanced binding aﬃnity and superior
selectivity for G4 structures over duplex DNA.
4.8. Octahedral metal complexes with planar ligands
With few exceptions, all metal complexes described above
possess planar geometry due to the planar macrocyclic or non-
macrocyclic polydentate ligands coordinated to various metal
centres. Several octahedral metal complexes such as Ru(II),
Ir(III), Fe(III) ion centres with planar ligands have also been
investigated as potent G4-ligands (Fig. 13), e.g. ruthenium(II)
polypyridyl complexes. Ruthenium complexes were initially
developed as alternatives to platinum anticancer drugs
because of their prominent DNA binding properties and out-
standing anticancer activity.2,93 One of the most recently
examined complexes 147 [Ru(bpy)2(dppz)]
2+ is known as a
molecular “light switch” for DNA that can intercalate between
the duplex DNA base pairs by π–π stacking.94,95 This obser-
vation prompted scientists to direct eﬀorts towards the
construction of Ru(II) complexes as G4-ligands. Recent
research shows that the complexes [Ru(bpy)2(dppz)]
2+ 147 and
[Ru(phen)2(dppz)]
2+ 148 serve as a prominent molecular “light
switch” not only for duplex DNA but also for G4 DNA in Na+ or
K+ containing buﬀer.96,97 However, the aﬃnity and selectivity
of these complexes towards G4 DNA was rather weak and their
G4 stabilization eﬀect was not prominent (ΔTm < 1 °C with
complex/G4 = 0.75 : 1). An enhancement of the stabilization
eﬀect and selectivity for the G-quadruplex could be achieved
by suitably modifying the polypyridyl ligand of the Ru
complexes. For example, the ruthenium complex 149,
[Ru(bpy)2dppz-idzo]
2+ with an imidazolone substituent on the
dppz ligand, was constructed,98 exhibiting not only a remark-
able “light switch” eﬀect for G4 DNA in K+ containing solution
(300-fold enhancement in emission) but also a powerful ability
to induce and stabilize the formation of the antiparallel G4
structure in buﬀer solution without alkali–metal ions.98 Its
powerful G4 stabilization ability was evident from the signifi-
cant increase in the melting temperature of G4 DNA being
stronger than that of the classic [Ru(bpy)2(dppz)]
2+ complex,
implying its great potential to act as a telomerase inhibitor
and an anti-cancer agent. Two other Ru(II) polypyridyl deriva-
Fig. 12 Platinum(II)–terpyridine complexes and derivatives reported as G4-ligands, the monodentate ligand is either a labile chloride or an alkynyl
moiety.85–88,90–92
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tives 150–151 bearing flexible cyclic amine-based side chains
on the large planar aromatic ligand were also constructed by
Chao et al.99 Measurements by using CD spectroscopy, FRET
and PCR-stop assays proved that these complexes could eﬀec-
tively bind with and stabilize G-quadruplex structures (ΔTm =
5–15 °C), thus exhibiting a concentration-dependent inhibitory
eﬀect on telomerase activity (IC50-TRAP = 100–500 nM), ulti-
mately resulting in long-term anti-proliferation of cancer cells.
Similarly, [Ru(dppz)2(bpy)]
2+ derivatives 153–154 bearing two
dppz ligands and one modified bpy moiety with two quatern-
ary ammonium pendants, again exhibited stronger inter-
actions with G4 DNA than the classic [Ru(bpy)2(dppz)]
2+ and
increased the melting temperature of G4 DNA by 7.0–9.4 °C.100
Lately, a series of Ru(II) polypyridyl complexes 155–158 con-
taining the phenyl-imidazo-[4,5f ][1,10] phenanthroline ligand
were also shown to stabilize the formation of G-quadruplex
structures, such as hTel G4 and c-myc G4 (ΔTm = 9–18 °C), via
optical spectroscopy, FRET and PCR-stop assays, resulting in
eﬀective inhibition of telomerase in the TRAP assay.101–104
Moreover, cellular studies such as cytotoxicity and flow cyto-
metric analysis of mitochondrial membrane potential found
that these complexes inhibited the growth of cancer cells
through eﬀectively promoting cell apoptosis, resulting in anti-
proliferative activities at low micromolar ranges comparable
with cisplatin.
A series of octahedral cyclometallic Ir(III) complexes have
been constructed as molecular “light switch” for G4 DNA.105
Upon binding with a G-quadruplex, these complexes exhibit a
luminescence enhancement, the magnitude of which is higher
than that upon binding with duplex DNA. The diﬀerence in
the emission intensity of these Ir(III) complexes suggest a mod-
erate selectivity for the G-quadruplex over duplex DNA, but
their G4-mediated anticancer activity was not discussed.
The octahedral Fe(III) complex 159 contains two meloxicam
ligands and also induces and stabilizes the hTel G4 structure
with good aﬃnity and selectivity as shown by UV/Vis, fluo-
rescence and CD spectroscopy as well as PCR-stop assays.106
Although the binding constant between 159 and hTel G4 (4.53
× 105 M−1) is smaller than that of most Pt(II) complexes, it is
an order of magnitude higher than that for the interaction
with duplex DNA. According to molecular modelling, the
binding mode between the Fe(III) complex and the G4 structure
is end-stacking of the meloxicam ligand on the terminal
G-quartet.
Fig. 13 Octahedral ruthenium(II) polypyridyl complexes and a Fe(III) complex containing two meloxicam ligands reported as G4-ligands.94–104,106
Review Inorganic Chemistry Frontiers
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Because of the octahedral geometry of these metal com-
plexes, the metal centre and the entire molecule is unlikely to
end-stack on or intercalate into the G-quartets. It is actually
the aromatic ligand with its large π-delocalized planar surface,
such as the meloxicam and the dppz ligand, that adopts the
end-stacking or intercalation binding mode with G-quartets. At
the same time the cationic properties of the entire molecule
caused by the metal centre further enhanced the aﬃnity to the
negatively charged DNA backbone at the grooves and loops.
4.9. Exceptions: introduction of metal centres reducing the
binding capability of organic G4-ligands
In all cases discussed above, regardless of whether the initial
ligand was planar or not, the introduction of the metal ion
centres resulted in a stronger interaction with G4 DNA by
oﬀering a more optimal molecular geometry and cationic pro-
perties. The rational modification of the ligand can further
improve the aﬃnity and selectivity towards G4 DNA. However,
there are also adverse cases in which the introduction of the
metal ion breaks the initially planar π-delocalized surface of
the ligand, resulting in a dramatic weakening of the binding
with G4 DNA.107,108 A representative member is the bisquinoli-
nium ligand 160, which has a large π-delocalized surface and
is one of the most selective G4 binders with highest aﬃnity.
However, addition of Cu(II) to a solution of a G4-bisquinoli-
nium mixture leads to unfolding of the G4 structure into a
single strand meaning that the stabilizing eﬀect of the bisqui-
nolinium ligand is dramatically weakened by the coordination
of Cu(II) (Fig. 14).107 Presumably this eﬀect is due to the
change of the planar geometry of the free bisquinolinium
ligand to a tilted arrangement upon coordination of Cu(II).
4.10. Multinuclear metal assemblies
Besides the monometallic complexes, a series of rationally
designed multinuclear metal assemblies are also described as
eﬀective G4-ligands and potent polymerase inhibitors. Their
binding modes can also be end-stacking, groove binding, loop
binding and others depending on the geometry of the
supramolecules.
Multinuclear platinum complexes are the most widely
investigated supramolecular G4-ligands. In previous studies
dimetallic Pt(II) and Pd(II) complexes with bis-carboxamido
pyridines were synthesized as potent G4-ligands because of
their planar surface oﬀering favourable geometry for stacking
with G4 DNA. However, the dimetallic Pt(II) structure 172 only
exists in the solid state but dissociates in solution to the
monometallic complex. It is actually this monometallic
complex that subsequently interacts with the G-quadruplex.109
However, the related dimetallic palladium(II) complex 173 with
bis-carboxamido pyridines is not a good G4-ligand, probably
because of its poor solubility.109 A number of monometallic
variants of this dimetallic Pd(II) complex with various side
arms were also described, but only the positively charged
complex containing the tertiary amine-modified side arms can
moderately stabilize hTel G4 DNA.109
The first stable multimetallic G4-ligand and telomerase
inhibitor described is the tetranuclear platinum(II) molecular
square 162 reported by Kieltyka et al., which is a representative
of the class of multinuclear metal assemblies with flat sur-
faces.110 This square arrangement has four [Pt(en)]2+ at the
corners and four 4,4′-bipyridyl as bridging ligands. This
complex has a flat surface for eﬀective end-stacking to the
terminal G-quartet and is highly positive charged for strong
electrostatic interactions with the DNA backbone. The
ethylenediamine ligands of the Pt(II) ions at the corners also
allow hydrogen bonding with the DNA backbone, further
improving the binding aﬃnity with G4. As a result, this
complex strongly stabilizes hTel G4 (ΔTm = 34.5 °C, FRET
assay) with high selectivity, the telomerase inhibition activity
also being very high (IC50-TRAP = 0.2 μM, in vitro TRAP assay).
Based on this representative compound, our group also syn-
thesized a series of four-nuclear Pt(II) assemblies with
diﬀerent bridging ligands trying to understand the structure–
activity relationship for G4 interactions.111,112 For example, the
platinum supramolecular square 164 with pyridyl as the brid-
ging ligand also stabilizes G4 DNA (hTel and c-kit promoter)
by end-stacking with the terminal G-quartets (binding ratio of
complex/DNA = 2 : 1), but the selectivity is not prominent.
FRET assays showed a complex-induced increase in melting
temperature by ca. 27.4 °C for hTel and 8.5 °C for duplex DNA,
respectively.111 This eﬀect was assigned to the relatively
smaller size of the flat surface compared to the previously
reported 4,4′-bipyridyl bridging analogues 162, the geometry
size of the latter was perfectly matching the size of G-quartets
(10.8 Å). Further studies of the four-nuclear Pt(II) quasi-cubes
163 exhibit enhanced selectivity towards G4 over duplex
DNA.112 The complex-induced increase in melting temperature
was ca. 33.5 °C for hTel and less than 1 °C for duplex DNA,
with a binding constant for G4 being two orders of magnitude
higher than that for duplex DNA. The binding ratio between
complex 163 and G4 was unexpectedly high (complex/DNA =
6 : 1) and molecular docking studies suggested both end-stack-
ing and groove-binding modes. All these Pt(II) squares and
Pt(II) quasi-cubes acted as eﬀective telomerase inhibitors, with
IC50-TRAP values ranging from 0.12 to 0.35 μM.
The first stable tri-nuclear and di-nuclear Pt(II) complexes
165–166 acting as eﬀective G4-ligands and telomerase inhibi-
tors were synthesized by our group, the Pt(II) corners of which
are bridged by a (quaternized-)trigeminal chelating
ligand.34,113,114 Both FRET and ITC assays indicated high
aﬃnity and excellent selectivity of these complexes for hTel G4
(ΔTm > 30 °C) over promoter c-myc and bcl-2 (ΔTm < 6.0 °C) as
Fig. 14 Bisquinolinium is a selective G4-ligand and its coordination to
Cu(II) causes a planar-to-linear conformational transition.107,108
Inorganic Chemistry Frontiers Review
This journal is © the Partner Organisations 2017 Inorg. Chem. Front., 2017, 4, 10–32 | 23
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
Se
pt
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 9
/2
1/
20
18
 1
1:
21
:0
0 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
well as duplex DNA (ΔTm < 1.5 °C). The PCR-stop and in vitro
TRAP assays indicate that these complexes eﬀectively induced
hTel G4 formation thereby eﬀectively inhibiting telomerase
activity with IC50-TRAP values in the micromolar range.
Interestingly, the V-shaped bi-nuclear Pt(II) complexes 166
favour to induce the hybrid parallel/antiparallel hTel G4 topo-
logy while the propeller-shaped trinuclear platinum(II) com-
plexes allow the recognition of diﬀerent G4 topologies with
diﬀerent Pt(II) corners, possibly due to their flexibility.114 For
example, the complex with diethylenetriamine Pt(II) corners
stabilizes antiparallel G4, while the complex with bis-(2-pyri-
dylmethyl)amine Pt(II) corners stabilizes parallel G4. Based on
the V-shaped bi-nuclear Pt(II) complex, we reported the first
nitroxide tagged G4-ligand 167 as a new strategy for investi-
gating detailed interactions between small molecules and the
G-quadruplex.113 Using the nitroxide moiety as a spin label,
the inter-spin distance between the two G4-bound 167 could
be measured by using electron paramagnetic resonance (EPR)
spectroscopy. Combining the EPR-measured data with mole-
cular docking revealed that this complex predominately binds
to the neighbouring-grooves as hTel adopts the antiparallel
conformation. Very recently, four dinuclear Pt(II)–terpyridine
complexes 168–171 were also reported to act as eﬃcient G4-
ligands, with high selectivity (ΔTm up to 17 °C) over duplex
DNA (ΔTm = 1 °C).115
Multimetallic supramolecules based on non-platinum
metal centres, such as Ru(II), Ni(II), Cu(II), Zn(II), Fe(II), Tb(III),
or Ce(IV), were also investigated as G4-ligands (Fig. 16–19).
Among them, the multimetallic Ru(II) complexes possess
additional excellent fluorescence emissive properties and their
interaction with G4 DNA is in some cases accompanied by
great changes in their optical properties. For example, the
binuclear Ru(II) complexes 175–176 (Fig. 16) are virtually non-
luminescent in aqueous solution, however upon binding with
the G4 DNA (d[AG3(T2AG3)3]) in the presence of K
+ ions the
emission is significantly enhanced (150-fold) accompanied by
a blue shift of 30 nm.97,116 It is worth mentioning that the
emission enhancement of the Ru(II) complexes is only
observed upon binding to G4 structures containing lateral
loops that are at least 3 base pairs long. Thus it is proposed
that the possible G4 binding mode is “end-pasting” or “thread-
ing” through the G4 lateral loops, in addition to partial inter-
calation. More interestingly, these dinuclear Ru(II) complexes
can be obtained in enantiomerically pure forms and thus oﬀer
Fig. 15 Multimetallic platinum(II) complexes reported as selective G4-ligands. Complex 167 was utilized for EPR measurement thus precisely deter-
mining the binding mode and binding sites of the Pt(II) complex.109–115
Review Inorganic Chemistry Frontiers
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novel enantio-selectivity for interacting with hTel G4 DNA of
antiparallel basket-like topology.117
Although the complexes discussed above moderately stabil-
ize G4 DNA (ΔTm = 3.8–5.4 °C in thermal melting experi-
ments), their selectivity towards G4 over duplex DNA is not
optimal: they can also bind to duplex DNA with high aﬃnity,
resulting in a moderate emission enhancement (50-fold) as
well. Changing the bridging ligand tppz to obip, a second-
generation luminescent bimetallic complex 177 is obtained,
displaying relatively better selectivity towards G4 DNA. The
emission enhancement of 178 with G4 is one order of magni-
tude higher than that for duplex DNA, and the complex/G4
interaction increases the melting temperature by 5.8–9.4 °C in
the presence of alkali metal cations.118 Chao et al. constructed
a series of comparative dinuclear Ru(II) complexes 178–181
with larger sized bridging ligands, exhibiting high selectivity
Fig. 16 Multimetallic ruthenium(II) polypyridyl complexes reported as G4-ligands. The bridging ligands are either rigid or ﬂexible.116–121
Fig. 17 Other examples of bimetallic complexes with homogeneous or heterogeneous metal centres reported as G4-ligands;122,123 Monometallic
Zn(II) macrocyclic complexes utilize the thymine residues as the primary mode of recognition.124–126
Inorganic Chemistry Frontiers Review
This journal is © the Partner Organisations 2017 Inorg. Chem. Front., 2017, 4, 10–32 | 25
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
Se
pt
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 9
/2
1/
20
18
 1
1:
21
:0
0 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
for binding with G4 over duplex DNA. These complexes can
induce and stabilize antiparallel hTel G4 (ΔTm = 12–24 °C) in
the presence or absence of K+ with 1 : 1 stoichiometry, leading
to promising inhibition eﬀects on telomerase activity and
cancer cell proliferation.119 In addition, two trigeminal ligand
bridged trinuclear ruthenium(II) complexes 182–183 were also
reported to moderately stabilize G4 DNA (ΔTm = 14–19 °C with
complex/DNA = 5 : 1) but the information about the selectivity
between G4 and duplex DNA is not available.120 These investi-
gations indicate that bridging ligands with appropriately sized
planar surfaces are essential for the strong and selective inter-
action of the multimetallic Ru(II) complexes with the
G-quadruplex.
All the multimetallic Ru(II) complexes described above are
bridged by a rigid, planar bridging ligand with extensive aro-
maticity. In addition, a novel bimetallic Ru(II) complex 184 is
Fig. 18 The cylinder-like bimetallic Ni(II) complex exhibits excellent chirality-based selectivity,129 and terbium(III)–amino acid complexes capable of
binding with i-motif DNA.130
Fig. 19 Metal complexes acting as G4 DNA-cleavage agents.131–136
Review Inorganic Chemistry Frontiers
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reported in which two octahedral fluorescent Ru(II) monomers
are connected with a partially flexible chain (noncyclic crown
ethers).121 Compared to other bimetallic Ru(II) complexes, this
complex shows a highly distinct fluorescence upon binding to
G4 compared to duplex DNA, the intensity diﬀerence of which
can even be distinguished by the naked eye. This indicates a
relatively high selectivity toward G4, the binding constant of
which is about one order of magnitude higher than that for
duplex DNA. This complex also moderately stabilizes the G4
structure (ΔTm = 12.7 °C) and was also considered as a potent
telomerase inhibitor.
Besides multimetallic Pt(II) and Ru(II) complexes, several
bimetallic terpyridyl-containing complexes with either homo-
geneous or heterogeneous metal centres were also reported as
eﬀective G4 binders (Fig. 17). For example, a dinuclear Cu(II)–
terpyridine complex 185 eﬀectively binds G4 DNA with very
high aﬃnity and stabilizes the antiparallel topology, and its
selectivity for G4 is 100-fold higher than that for duplex
DNA.122 Bimetallic complexes 186–189 with either homo-
geneous or heterogeneous metal centres, e.g. Zn(II)/Zn(II),
Cu(II)/Cu(II), Pt(II)/Zn(II), Pt(II)/Cu(II), were also constructed
based on a novel terpyridine–cyclen ligand, both the ter-
pyridne and cyclen moieties of which possessed eﬃcient metal
chelating properties. These dinuclear complexes all exhibited
higher binding aﬃnities towards G4 compared to their mono-
metallic counterparts.123 In addition, Morrow et al. reported
two Zn(II) macrocyclic complexes 190–191, the structures of
which were similar to the monometallic counterparts of
complex 186 with the nonplanar dansyl group and acridine
group pendents, respectively.124–126 Complex 190 shows
110-fold selectivity in binding to hTel G4 over duplex DNA,
evidenced by an increase in the fluorescence and a simul-
taneous shift in emission upon G4 interaction. ITC,
fluorescence and NMR spectroscopy give a complex/G4
stoichiometry of 2 : 1 and indicate one complex binding to two
spaced thymines within two separate loops in the hTel G4.
Notably, this is the first reported metal complex-based hTel
G4-ligand utilizing the thymine residues as the primary mode
of recognition. Although loop bindings have also been found
in several previously reported G4-ligands, they were mainly the
secondary mode of interaction and driven through aromatic
stacking.127,128 As a comparison, complex 191 containing an
acridine pendent shows stronger binding to the G-quadruplex
but indiscriminately binds to duplex DNA as well.
A novel cylinder-like bimetallic Ni(II) complex 192 (Fig. 18)
with triple diimine ditopic ligands was constructed by Qu and
co-workers, exhibiting a novel chirality-based selectivity for
hTel G4 structure over the duplex as well as other diﬀerent
types of G4 DNA.129 Only the P-enantiomer of this supramole-
cular cylinder selectively stabilizes hTel G4 DNA and simul-
taneously induces an antiparallel-to-hybrid conformational
transition in the presence of Na+. The stoichiometry ratio
complex/G4 was determined to be 1 : 1 and an S1 nuclease
cleavage assay was performed to determine whether the
complex binds with an end-stacking binding mode with the
cylinder stacking on top of the terminal G-quartet via its exten-
sive hydrophobic exterior. In addition, the positively charged
metal ion centres allow strong electrostatic interactions with
loops and grooves, so that the termini of the hTel G4 are pro-
tected from the S1 nuclease cleavage. This example paved the
way towards the development of a new class of G4-targeted
chiral binders and anticancer drug candidates. In addition,
two bimetallic terbium(III)–amino acid complexes 193–194 are
capable of binding hTel G4 DNA as well as i-motif DNA,
although the binding constant and stabilization eﬀect were as
good as found for previously described metal complexes.130
4.11. Metal assemblies as G4 DNA-cleavage agents
In the examples presented above, the metal complexes eﬀec-
tively stabilize certain G-quadruplex structures thus inhibiting
telomerase activity or oncogene expression, ultimately interfer-
ing with telomere maintenance and preventing the prolifer-
ation of cancer cells eﬀectively. However, this strategy usually
requires long-term treatment to significantly shorten the telo-
mere length of cancer cells, because each round of cell division
only reduces 50–200 nt of the telomere length. Thus several
metal-containing G4-ligands have recently been reported to
induce direct cleavage of G4 DNA as another anticancer strat-
egy. The first reported metal complex acting as a G4 DNA clea-
vage agent was a highly reactive high-valent oxo-manganese
porphyrin species 195, which was formed in situ from the
Mn(III)–TMPyP4 complex 7 in the presence of the oxygen atom
donor, KHSO5 (Fig. 19).
131 During the redox reaction only one
face of the porphyrin is solvent accessible which is consistent
with the partial stacking of the metalloporphyrin on the
external side of the terminal G-quartet. The in situ formed
Mn(V)vO species from the Mn(III)–TMPyP4/KHSO5 system can
act as nuclease mediating oxidative cleavage of the bound hTel
G4 sequence. Such oxidative damage consisted of both
guanine oxidation within the interacting G-quartet and the
1′-carbon hydroxylation of deoxyriboses carrying thymidine
residues located on the neighboring single-stranded loop.
However, this highly reactive Mn(V)vO species cleaves both
hTel G4 and duplex DNA indiscriminately, indicating that
improved targeting and selective cleavage towards hTel G4
structures are still required.131
Afterwards a water-soluble dimetallic Fe(II)–EDTA complex
196 bridged by the planar polyaromatic ligand perylene was
constructed as a selective G4 DNA cleavage agent
(Fig. 19).132,133 The bridging perylene ligand is known as an
eﬀective G4 binder, allowing π-stacking of the dimetallic
complex on the terminal G-quartets, and two Fe(II)-EDTA cores
bind with the opposite grooves. Upon interaction, this
complex selectively cleaves the G-quadruplex over duplex DNA
in the presence of the reducing agent, dithiothreitol, probably
through a hydroxyl radical mechanism.132,133
The dimetallic Ce(IV) complex 197 with ethylenediamine–
tetramethylene phosphonic acid (EDTP) has recently been
reported as a selective DNA-cleavage agent for intermolecular
G-quadruplex DNA (Fig. 19).134 This complex can induce the
assembly of a highly stable (3 + 1) intermolecular G4 structure
by covalently binding to the G-rich sequence, and such a
Inorganic Chemistry Frontiers Review
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Ce(IV)-EDTP–DNA conjugate can further induce sequence-
specific hydrolytic cleavage at a specific phosphodiester site of
the hTel G4 DNA backbone. However, this complex possesses
some inherent disadvantages e.g. low cellular uptake, instabil-
ity to natural nucleases, self-cleavage, which limit its further
applications and investigations in vivo.
Very recently, a novel DNA-cleaving agent 198 has been
reported to be capable of selectively cleaving intramolecular
hTel G4 DNA.135,136 This complex is constructed by coupling
an amino-terminal copper binding motif peptide GGHK to an
acridine-based G4 ligand (Fig. 19). The acridine moiety pro-
motes the selective binding of the complex towards hTel G4
over duplex DNA, and helps in positioning the catalytic metal-
lodrug moiety CuGGH in close proximity to G4 DNA. Based on
this G4 targeting property, complex 198 could selectively and
eﬃciently induce irreversible cleavage on the G4 structure
rather than other structural states of telomeric DNA in the
presence of redox co-reagents. The 3′overhang cleavage
product was generated from both hydrolysis and oxidative clea-
vage mechanisms. Data from molecular modelling and
MALDI-MS suggested the major selective cleavage sites at A1-
G2 and T6-A7 nucleotides. As a result, complex 198 caused the
significant shortening of telomeric DNA, cellular senescence
and apoptosis in MCF7 cell lines.
5. Conclusions
G-quadruplex nucleic acids are formed by self-assembly of
guanine-rich sequences and can be found in telomeres, onco-
gene promoters, and non-translated RNA regions. They
possess unique structures distinct from the well-known double
helical structures adopted by most genomic DNA. Such dis-
tinct structures oﬀer a great opportunity for selective mole-
cular recognition toward the G-quadruplex over genomic
duplex DNA. Moreover, formation of G4 nucleic acids inter-
feres with numerous biological pathways, including mainten-
ance of telomeres, regulation of oncogene transcription and
translation and so on. Once intramolecular G4 is formed
within the human telomeric DNA sequence, the activity of telo-
merase is indirectly inhibited due to the loss of the substrate,
resulting in telomere shortening in cancer cells. Because telo-
merase is silent in normal cells but up-regulated in most
cancer cells contributing to their immortality, molecules
capable of inhibiting or down-regulating telomerase activity
thereby has the potential for selective toxicity toward cancer
cells over normal cells. Intramolecular G4 formed within the
oncogene promoter regions could lead to the inhibition of
oncogene expression, thus exhibiting selective toxicity toward
cancer cells as well. Thus G4 nucleic acids have attracted a lot
of attention as potential clinical targets for the development of
new types of anticancer agents.
Small molecules that can recognize and interact with the
G-quadruplex with high aﬃnity and specificity, termed G4-
ligands, have been systematically investigated over the past few
decades. Their capabilities to act as G-quadruplex stabilizers,
telomerase activity inhibitors, oncogene transcription and
translation modulators, as well as DNA-cleavage agents have
been assessed, thus opening new avenues for cancer chemo-
therapy. This review summarizes the various families of metal
complexes reported in the literature that have G4 DNA target-
ing properties so as to exhibit potent anticancer eﬀects
through selectively stabilizing or cleaving the G-quadruplex over
duplex DNA. The majority of understanding has focused on the
G4 DNA at telomeres and promoter regions although
G-quadruplex motifs are definitely present in other regions of
the genome. These metal complexes possess peculiar tridimen-
sional geometries, such as square-planar in most cases, square-
based pyramidal, cube-like shape or even an octahedral struc-
ture, and the metal ions must arrange the scaﬀold into the
optimal geometry for G4 binding. In fact, diﬀerent metal
centres coordinating with the same organic ligand can generate
metal complexes with overall distinct G4 binding properties.
The interactions between the metal complexes and
G-quadruplex have been characterized by numerous biophysi-
cal methods revealing the strength and specificity of these G4-
ligand interactions. A summary of current knowledge of metal-
containing G4-ligands concludes three main binding sites: the
G-quartets, the grooves, and the loops of the G-quadruplex.
The large majority of known G4-ligands exhibit a preference
for the first binding site, usually end-stacking of the metal
complex scaﬀold onto one of the terminal G-quartets. To opti-
mize this end-stacking binding mode, metal complexes
reported in the literature generally present a suitably sized
planar surface, which is larger than that involved in DNA inter-
calators so as to eliminate the possibility of intercalation
binding mode. In some cases the scaﬀold of metal complexes
is flexible but attains planarity upon end-stacking onto the
external G-quartet. On the other hand, the presence of bulky
flexible side chains at the periphery of the central planar core
increases the steric hindrance of the metal complexes, which
could prevent the intercalation mode of G4-ligands between
DNA base pairs. Moreover, positively charged or protonable
side chains can not only enhance electrostatic interaction
strength with the negatively charged DNA phosphate backbone
but also improve the fitting of the molecule into the grooves,
loop residues or cavities, resulting in an increase in the aﬃnity
of the G4-ligands. All these structural design considerations
are beneficial for increasing the selectivity of metal complexes
for G4 over duplex DNA.
Although the majority of G4-ligands reported so far
recognize G-quartets and present end-stacking binding mode,
this interaction can only allow a selective discrimination
between G4 and duplex DNA, it can hardly distinguish one G4
structure over another. This is not therapeutically eﬀective
enough. As a consequence more promising binding modes,
such as groove binding and loop binding, are favourable
for the enhancement of selectivity. Because diﬀerent
G-quadruplex topologies endow grooves and loops with
various dimensions and accessibilities, G4-ligands presenting
specific groove or loop binding modes have great potential to
discriminate among diﬀerent G4 DNA derived from various
Review Inorganic Chemistry Frontiers
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G-rich sequences. It is a big challenge to combine targeting of
the grooves/loops with targeting of the G-quartets and to date
this has only provided limited success. In these examples mul-
tiple binding modes can occur simultaneously, but groove/
loop binding are mainly the secondary mode of interaction
and usually driven through the primary mode of interaction
end-stacking. Only a few bimetallic Pt(II), bimetallic Ru(II) and
macrocyclic Zn(II) complexes utilize the grooves and loops as
the primary mode of recognition. This provides great inspi-
ration for the design of the next generation of G4-ligands that
depends less on general G-quartet but more on specific
groove/loop recognition.
Besides π stacking and groove/loop binding, metal com-
plexes containing labile groups (Cl, H2O, etc.) can also make
direct coordination of the metal centre to G4 DNA nucleo-
bases, similar to the platination of duplex DNA by cisplatin.
This type of coordination either occurs at a single nucleotide,
in most cases guanines, or causes cross-linking of two nucleo-
bases, probably enhancing the aﬃnity and specificity of the
metal complexes to G4 DNA, similar to the compounds
131–132. Regardless of the kind of binding mode, these metal-
containing G4-ligands eﬀectively stabilize certain
G-quadruplex structures, thus inhibiting telomerase activity or
oncogene expression, ultimately interfering with telomere
maintenance and inhibiting the proliferation of cancer cells.
On the other hand, several rationally designed metal com-
plexes have very recently been reported possessing the property
to selectively cleave hTel G4 over duplex DNA through either
oxidative damage or hydrolysis mechanism. These cleavage
processes require the presence of redox co-reagents – hydro-
lysis cleavage and oxidative damage. This is considered as
another anticancer strategy, which can significantly shorten
the telomere length of cancer cells in a relatively shorter term
rather than other G4 stabilizers.
From all these studies, the rational design of metal com-
plexes to selectively interact with, stabilize or cleave
G-quadruplex structures has evolved as a promising strategy
for the development of anticancer drugs with selective toxicity
towards cancer cells over normal ones. However, the G4-ligand
development has been dominated by in vitro biophysical and
biochemical investigations, the understanding of G4-ligand
activity and selectivity in the in vivo environment still remains
a major challenge. After so many years only one promising in
vivo G4-ligand, Quarfloxin, has reached phase II clinical trials
for treating neuroendocrine tumors and carcinoid tumors.30
Upon its binding with the G-quadruplex structure in the ribo-
somal DNA (rDNA) template, the interaction between nucleolin
protein and rDNA is disrupted, resulting in the inhibition of
rRNA biogenesis and ribosome synthesis in cancer cells.
Similar ribosomal DNA G4-targeted metal complexes have not
been reported. This may shed light on the development of
rDNA G4-targeted metal complexes for clinical use.
The structures of G4 sequences in vivo are highly dynamic,
which may be in its linear form or interacting with proteins. In
this sense there are two critical questions that need to be
addressed for the development of G4-targeted drugs: what are
the in vivo targets of these G4-ligands and how to control their
accessibility? Thus it is important for the G4-ligands not only to
recognize the G4 arrangement already organized but also to
reach the target and induce the formation of G4 conformation.
Several metal complexes have been reported capable of inducing
the formation of certain G4 conformations and those possessing
distinct photophysical properties can be used as “light switches”
for G-quadruplexes to monitor the occurrence of G4 structures
even in living cells. Thus it is probably possible to design
G4-ligands capable of simultaneously inducing and real-time
tracing the occurrence of G4 structures during cancer therapy.
The chirality-based selectivity of metal complexes is also very
attractive for designing G4-ligands: diﬀerent enantiomers can
recognize diﬀerent G4 topologies and even show diﬀerential
uptake mechanisms and cellular localization. The utilization of
these metal complexes as in vivo probes for G4 DNA or as
unique photosensitizers is also likely to be an active area.
Additionally, an important first step in designing selective
G4 DNA-cleavage agents has been taken by application of a
catalytic metallodrugs’ strategy, in which metal complexes act
as an artificial nuclease mediating the hydrolysis or oxidative
cleavage of telomeric DNA. The combination of metallodrugs
and G4 DNA binding may also catalyze oxidation directing
toward small substrates present in the bulk, thus becoming a
DNAzyme. For example, a heme cofactor of natural enzymes
known as iron(III) protoporphyrin IX (or Hemin) is endowed
with G-quadruplex binding capability with high aﬃnity, and
the hemin-binding G4 DNA aptamer has been found to exhibit
peroxidase-like activity which can be used as a sensitive probe
for the identification of single nucleotide polymorphisms by
giving a color signal.137,138 This may open new avenues for the
application of metal-containing G4-ligands as attractive cata-
lytic labels in biosensing.
In summary, development of metal-containing G4-ligands
as novel anti-cancer drugs is a rapidly growing field. Despite
making some progress, to date the majority of metal-contain-
ing G4-ligands do not have realistic drug-like structures and
their in vivo applications are still very rare. Thus it is expected
that further advancement in this field will focus on progress in
medicinal studies and in the next few years we would like to
see new generations of metal-containing G4-ligands enter
clinical trials.
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